Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
LAURUSLABS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The NCLT Amaravati Bench has allowed the first motion application in Laurus Labs' composite scheme of arrangement involving two of its wholly-owned subsidiaries — Laurus Synthesis Pvt Ltd (LSPL, transferor/demerged) and Sriam Labs Pvt Ltd (resulting). Under the scheme, LSPL's Unit-1 (CDMO business) will be demerged into Sriam Labs, while the remaining business of LSPL will be amalgamated into Laurus Labs. The share exchange ratio for the demerger leg is 27 equity shares of Sriam Labs for every 1 share of LSPL. NCLT has dispensed with shareholder and creditor meetings of Laurus Labs, and the appointed date is April 1, 2026. Unsecured creditor meetings of LSPL and Sriam are scheduled for April 6, 2026.
This is an internal restructuring among wholly-owned subsidiaries with no dilution to public shareholders of Laurus Labs, as no new shares will be issued by the listed entity. The move aims to consolidate similar businesses, simplify the group structure, and improve operational efficiency — neutral to mildly positive for shareholders in the long run.